Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Isatuximabe em Combinação com Novos Agentes em RRMM - Protocolo Mestre

16 de novembro de 2026 atualizado por: Sanofi

Fase 1-2 Estudo UMBRELLA avaliando isatuximabe com ou sem dexametasona em combinação com novos agentes em comparação com isatuximabe com pomalidomida e dexametasona em mieloma múltiplo recidivante ou refratário (MMRR) - Protocolo mestre

The purpose of this umbrella study is to evaluate isatuximab when combined with novel agents with or without dexamethasone in participants with relapsed or refractory myeloma. Substudy 01 is the control Substudy. Substudies 02, 03, and 06 are controlled experimental substudies. Substudies 04 and 05 are independent experimental substudies.

Visão geral do estudo

Descrição detalhada

Participants will continue study treatment until disease progression, death, unacceptable toxicity, participant request to stop treatment, Investigator decision, or study termination by the Sponsor i.e., up to Aapproximately 28 months.

Tipo de estudo

Intervencional

Inscrição (Estimado)

258

Estágio

  • Fase 2
  • Fase 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Contato de estudo

  • Nome: Trial Transparency email recommended (Toll free number for US & Canada)
  • Número de telefone: option 6 800-633-1610
  • E-mail: contact-us@sanofi.com

Locais de estudo

      • Frankfurt, Alemanha, 60590
        • Recrutamento
        • Investigational Site Number : 2760006
      • Lübeck, Alemanha, 23562
        • Recrutamento
        • Investigational Site Number : 2760008
    • New South Wales
      • Wollongong, New South Wales, Austrália, 2500
        • Recrutamento
        • Investigational Site Number : 0360006
    • Victoria
      • Heidelberg, Victoria, Austrália, 3084
        • Concluído
        • Investigational Site Number : 0360003
      • Melbourne, Victoria, Austrália, 3065
        • Recrutamento
        • Investigational Site Number : 0360002
      • Richmond, Victoria, Austrália, 3121
        • Recrutamento
        • Investigational Site Number : 0360001
    • Seoul-teukbyeolsi
      • Seoul, Seoul-teukbyeolsi, Coréia do Sul, 03722
        • Recrutamento
        • Investigational Site Number : 4100004
      • Seoul, Seoul-teukbyeolsi, Coréia do Sul, 06351
        • Recrutamento
        • Investigational Site Number : 4100002
      • Seoul, Seoul-teukbyeolsi, Coréia do Sul, 03080
        • Recrutamento
        • Investigational Site Number : 4100001
      • Seoul, Seoul-teukbyeolsi, Coréia do Sul, 06591
        • Recrutamento
        • Investigational Site Number : 4100003
    • Alabama
      • Birmingham, Alabama, Estados Unidos, 35233
        • Concluído
        • University of Alabama at Birmingham- Site Number : 8400001
    • Georgia
      • Atlanta, Georgia, Estados Unidos, 30322
        • Recrutamento
        • Winship Cancer Institute of Emory University- Site Number : 8400010
    • Illinois
      • Chicago, Illinois, Estados Unidos, 60612
        • Concluído
        • University of Illinois-Chicago - College of Medicine- Site Number : 8400007
    • Michigan
      • Ann Arbor, Michigan, Estados Unidos, 48109
        • Recrutamento
        • University of Michigan Health System - Ann Arbor- Site Number : 8400004
    • New York
      • Buffalo, New York, Estados Unidos, 14263
        • Recrutamento
        • Roswell Park Cancer Institute- Site Number : 8400008
    • Ohio
      • Columbus, Ohio, Estados Unidos, 43210
        • Recrutamento
        • The Ohio State University- Site Number : 8400012
      • Lille, França, 59037
        • Recrutamento
        • Investigational Site Number : 2500002
      • Nantes, França, 44093
        • Recrutamento
        • Investigational Site Number : 2500001
      • Paris, França, 75013
        • Recrutamento
        • Investigational Site Number : 2500003
      • Paris, França, 75015
        • Recrutamento
        • Investigational Site Number : 2500004
      • Athens, Grécia, 115 28
        • Recrutamento
        • Investigational Site Number : 3000001
      • Athens, Grécia, 106 76
        • Recrutamento
        • Investigational Site Number : 3000002
      • Jerusalem, Israel, 9112001
        • Recrutamento
        • Investigational Site Number : 3760002
      • Ramat Gan, Israel, 5262100
        • Recrutamento
        • Investigational Site Number : 3760003
      • Tel Aviv, Israel, 6423906
        • Recrutamento
        • Investigational Site Number : 3760001
    • Reggio Emilia
      • Meldola, Reggio Emilia, Itália, 47014
        • Recrutamento
        • Investigational Site Number : 3800001
      • Oslo, Noruega, 0450
        • Recrutamento
        • Investigational Site Number : 5780001
    • Puerto Rico
      • Hato Rey, Puerto Rico, Porto Rico, 00917
        • Concluído
        • Puerto Rico Medical Research Center- Site Number : 8400005

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

18 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Não

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Participant must be 18 years of age inclusive or older.

  • Eastern Cooperative Oncology Group (ECOG) performance status 0-1.

  • Participants with relapsed or refractory MM who have received at least 2 prior lines of therapy for MM, including PIs and IMiDs (eg, Induction regimen with autologous stem cell transplant followed by maintenance is considered one line).

  • RRMM with measurable disease:

    • Serum M protein ≥0.5 g/dL measured using serum protein immunoelectrophoresis and/or
    • Urine M protein ≥200 mg/24 hours measured using urine protein immunoelectrophoresis and/or
    • Serum free light chain (sFLC) MM without measurable M protein in serum or urine per previous criteria (serum Ig free light chain ≥10 mg/dL and abnormal serum Ig kappa lambda free light chain ratio <0.26 or >1.65).
  • Men or woman or childbearing potential should agree to use contraception.

  • Substudy 01, 06: Anti-CD38 therapy naïve or prior exposure to such drugs with a wash out of at least 12 months after the last dose. "Exposure" is defined as at least 2 cycles of therapy.

  • Substudies 02, 03: Anti-CD38 therapy naïve or prior exposure to such drugs without being refractory but with a wash out of at least 6 months after the last dose. "Refractory" is defined as progressing within 60 days of last dose of anti-CD38 targeting therapy.

  • Substudy 04: Anti-CD38 and anti-B cell maturation antigen (BCMA) therapy (if available) prior exposed participants with RRMM. For anti-CD38, "Exposure" is defined as at least 2 cycles of therapy. For anti-BCMA therapy if available, exposure is defined by at least 2 cycles of therapy.

  • Substudy 05: Participants with RRMM with at least 2 cycles of prior exposure to anti-CD38 therapy. For participants to whom BCMA targeted therapy is available (ie, approved in their region and can be reimbursed), at least 2 cycles of prior exposure to a BCMA targeted agent is mandatory.

Exclusion Criteria:

  • Primary systemic amyloid light chain amyloidosis, plasma cell leukemia, monoclonal gammopathy of undetermined significance, or smoldering myeloma.
  • Uncontrolled infection within 14 days prior to first study intervention administration.
  • Clinically significant cardiac (including valvular) or vascular disease within 3 months prior to first study intervention administration., eg, myocardial infarction, unstable angina, coronary (eg, coronary artery bypass graft, percutaneous coronary intervention) or peripheral artery revascularization, left ventricular ejection fraction <40%, heart failure New York Heart Association Classes III and IV, stroke, transient ischemic attack, pulmonary embolism, other thromboembolic event, or cardiac arrhythmia (Grade 3 or higher by NCI CTCAE Version 5.0).
  • Known acquired immunodeficiency syndrome-related illness or known human immunodeficiency virus (HIV) disease requiring antiviral treatment or active hepatitis A.
  • Uncontrolled or active hepatitis B virus (HBV) infection.
  • Active hepatitis C virus (HCV) infection.
  • Any of the following within 3 months prior to first study intervention administration: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease.
  • Second malignancy other than basal cell or squamous cell carcinoma of the skin or in situ carcinoma, unless they are successfully treated with curative intent for more than 3 years before first study intervention administration.
  • Any anti-MM drug treatment within 14 days before first study intervention administration, including dexamethasone.
  • Participants with a contraindication to treatment.
  • Vaccination with a live vaccine 4 weeks before the start of the study.
  • Seasonal flu and COVID-19 vaccines that do not contain live virus are permitted.
  • Hemoglobin <8 g/dL.
  • Platelets <50 × 10^9/L.
  • Absolute neutrophil count <1.0 × 10^9/L.
  • Creatinine clearance <30 mL/min/1.73m2.
  • Total bilirubin >1.5 × ULN, except for known Gilbert syndrome in which direct bilirubin should be ≤2.5 × ULN.
  • Aspartate aminotransferase and/or alanine aminotransferase >3 × ULN.
  • Patients with grade 3 or 4 hypercalcemia.

Substudy 01:

-Malabsorption syndrome or any condition that can significantly impact the absorption of pomalidomide.

Substudy 02:

  • History of resected/ablated basal or squamous cell carcinoma (SCC) of the skin or carcinoma in situ of the cervix, or other local tumors, even if considered cured by local treatment.
  • Therapeutic doses of anticoagulants or antiplatelet agents within 7 days prior to the first dose of SAR439459.
  • Prothrombin time or INR >1.5 × upper limit of normal (ULN).

Substudy 03:

  • Current corneal epithelial disease except mild punctate keratopathy.
  • Patients who have received prior therapy with belantamab mafodotin.

Substudy 04:

  • Central nervous system or leptomeningeal disease.
  • Medical history of seizure.
  • Participants currently receiving hepatically metabolized narrow therapeutic index drugs (eg, digoxin, warfarin) if cannot be closely monitored.
  • Active, known, or suspected autoimmune disease that has required systemic treatment in the past 2 years (ie, with use of disease modifying agents, corticosteroids or immunosuppressive drugs), except controlled by replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc). The following are not exclusionary: vitiligo, childhood asthma that has resolved, psoriasis that does not require systemic treatment.
  • Prior allogeneic hematopoietic stem cell transplant (allo-HSCT).

Substudy 05:

- Participant unable to swallow tablets.

Substudy 06:

  • History of active autoimmune disorders.
  • History of autoimmune hemolytic anemia or autoimmune. thrombocytopenia.
  • Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD.
  • Prior allogenic hematopoietic stem cell transplant (allo-HSCT).
  • Patient with chronic active EBV infection.
  • Patients with known history of HLH.
  • Hemoglobin < 9 g/dL.
  • Prior therapy with any anti-CD47 or anti signal regulatory protein alpha agent.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Tratamento
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição Paralela
  • Mascaramento: Nenhum (rótulo aberto)

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Comparador Ativo: Control Arm: isatuximab + pomalidomide + dexamethasone (Substudy 01)
  • Isatuximab, intravenous (IV) doseweekly (QW) × 4 weeks (Cycle 1), followed by every two weeks (Q2W) (subsequent cycles).
  • Pomalidomide dose by mouth daily Day 1 to Day 21.
  • Dexamethasone dose by mouth QW.

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Outros nomes:
  • SAR650984
  • Sarclisa®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Capsule; Route of administration: Oral

Outros nomes:
  • Pomalyst®
Experimental: isatuximab + SAR439459 + dexamethasone (Substudy 02)

SAR439459 in combination with isatuximab and dexamethasone

Part 1:

2 dose levels (DLs) of IV SAR439459:

  • DL1 SAR439459 dose Q2W.
  • DL2 SAR439459 dose Q2W.
  • Isatuximab dose IV QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).
  • Dexamethasone fixed dose and schedule: QW by mouth In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).

Part 2:

  • SAR439459 IV dose Q2W.
  • Isatuximab IV dose QW × 5 weeks (Cycle 1), followed by Q2W administrations (subsequent cycles).
  • Dexamethasone fixed dose and schedule: QW by mouth. In Cycle 1, the first administration of SAR439459 (Day 1) will precede isatuximab by 1 week (first dose of isatuximab will be at Cycle 1 Day 8).

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Outros nomes:
  • SAR650984
  • Sarclisa®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Solution for injection; Route of administration: Intravenous

Experimental: isatuximab + dexamethasone + belantamab mafodotin (Substudy 03)

Belantamab mafodotin in combination with isatuximab and dexamethasone

Part 1:

1 DL of IV belantamab mafodotin in Part 1 and de-escalation dose DL-1:

  • DL1 belantamab mafodotin IV dose QW4 or de-escalation dose DL-1 QW8
  • Isatuximab dose, IV QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).
  • Dexamethasone fixed dose and schedule: QW by mouth.

Part 2:

  • Isatuximab IV dose QW × 4 weeks (Cycle 1), followed by Q2W (subsequent cycles).
  • Belantamab mafodotin IV dose Q4W or Q8W
  • Dexamethasone fixed dose and schedule: QW by mouth.

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Outros nomes:
  • SAR650984
  • Sarclisa®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Outros nomes:
  • BLENREP®
Experimental: Isatuximab + pegenzileukin (Substudy 04)

Pegenzileukin in combination with isatuximab

Part 1- dose escalation:

  • Up to 3 DLs of IV pegenzileukin are planned to be evaluated:

    • DL1 will explore pegenzileukin at Q2W.
    • DL2 will explore pegenzileukin at Q2W.
    • DL3 will explore pegenzileukin at Q2W.
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).

Part 1 - dose optimization:

  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).
  • Pegenzileukin at potential doses (DL A and DL B) Q2W.

Part 2 (dose expansion):

  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles).
  • Pegenzileukin IV dose Q2W.

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Outros nomes:
  • SAR650984
  • Sarclisa®

Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Outros nomes:
  • SAR444245
Experimental: Experimental: Isatuximab + Dexamethasone + Belumosudil (Substudy 05)

Isatuximab in combination with belumosudil and dexamethasone Part 1- dose escalation: During the first cycle, belumosudil will be evaluated in monotherapy during 2 to 4 weeks, then isatuximab and dexamethasone will be added, and continued for the subsequent cycles.

  • Belumosudil by mouth at Dose Level (DL) 1, DL2, DL3, and DL4
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Part 1- dose optimization:

  • Belumosudil at potential doses (DL A and DL B), daily by mouth
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Part 2- dose expansion:

  • Belumosudil dose daily, by mouth
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Outros nomes:
  • SAR650984
  • Sarclisa®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: tablet; route of administration: oral

Outros nomes:
  • Rezurock
  • SAR445761,
Experimental: Isatuximab + evorpacept + dexamethasone (Substudy 06)

Isatuximab in combination with evorpacept and dexamethasone

Part 1- dose escalation:

  • Evorpacept IV dose Q2W
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth Part 1- dose optimization
  • Evorpacept IV at potential doses (DL A and DL B), Q2W
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Part 2- dose expansion:

  • Evorpacept IV dose Q2W
  • Isatuximab IV dose QW × 4 weeks, followed by Q2W (subsequent cycles)
  • Dexamethasone fixed dose and schedule: QW by mouth

Pharmaceutical form: Concentrated solution for intravenous infusion; Route of administration: Intravenous infusion

Outros nomes:
  • SAR650984
  • Sarclisa®

Pharmaceutical form: Tablet; Route of administration: Oral

Pharmaceutical form: Solution for infusion; Route of administration: Intravenous

Outros nomes:
  • ALX148

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Part 1 (dose finding, experimental substudies): Determination of recommended dose of novel agents in combination with isatuximab
Prazo: Through the end of cycle 1 (approximately 6 weeks)

Determination or confirmation of the dose will be based on: safety and tolerability in terms of TEAEs/SAEs, dose-limiting toxicity occurrence, and laboratory parameters available information on PK (if appropriate) and biomarkers.

Through the end of cycle 1 (approximately 6 weeks)
Part 2 (expansion, controlled experimental substudies): VGPR Rate (Rate of Very Good Partial Response Rate or Better)
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 2 (expansion, independent experimental substudies): Overall Response Rate (ORR) in independent experimental substudies
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Concentração de novos agentes (braços experimentais) e isatuximabe (Ctrough)
Prazo: Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Concentração máxima observada após a primeira infusão (cmax) para belumosudil - subestudy 05
Prazo: Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Hora de chegar ao CMAX (TMAX) para Belumosudil - Substudy 05
Prazo: Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Área sob a curva de concentração versus tempo calculada usando o método trapezoidal de 0 a 8h (AUC0-8H) para belumosudil - subestudos 05
Prazo: Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Concentração máxima observada após a primeira infusão (CMAX) para evorpacept - Substudy 06
Prazo: Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Hora de chegar ao CMAX (TMAX) para Evorpacept - Substudy 06
Prazo: Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Área sob a curva de concentração versus tempo calculada usando o método trapezoidal sobre o intervalo de dosagem para EvorpacEPT (AUC0-T)- Substudy 06
Prazo: Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Vários pontos de tempo durante o ciclo 1. O ciclo é de 28 dias.
Part 1 (dose finding, experimental substudies): ORR
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 2 (expansion, controlled experimental substudies): ORR
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

ORR, defined as the proportion of participants with stringent complete response (sCR), complete response (CR), VGPR, or partial response (PR), according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 1 (dose finding, experimental substudies): VGPR or better
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Part 2 (expansion, independent experimental substudies): VGPR or better
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

VGPR or better rate is defined as the percentage of participants with a VGPR or better as defined by the 2016 IMWG response criteria, assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Clinical benefit rate (CBR) in each treatment arm
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

CBR, defined as the proportion of participants with sCR, CR, VGPR, PR, or minimal response, according to the 2016 IMWG criteria assessed by Investigator based on central laboratory values and local imaging.

Up to approximately 28 months after the First patient in or scheduled assessment
Duration of Response (DOR) in each treatment arm
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

DOR, defined as the time from the date of the first response that is subsequently confirmed for patients achieving PR or better to the date of first documented PD or death, whichever happens first.

Up to approximately 28 months after the First patient in or scheduled assessment
Time to First Response (TT1R) in each treatment arm
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

TT1R, defined as the time from the date of first treatment to the date of first response (PR or better) that is subsequently confirmed.

Up to approximately 28 months after the First patient in or scheduled assessment
Time to Best Response (TTBR) in each treatment arm
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

TTBR, defined as the time from the date of first treatment to the date of first occurrence of best overall response (PR or better) that is subsequently confirmed.

Up to approximately 28 months after the First patient in or scheduled assessment
Number of participants with treatment emergent adverse events and serious adverse events in each treatment arm
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

Safety and tolerability assessed in terms of adverse events/SAEs, including second primary malignancies, laboratory parameters, vital signs, and findings from physical examination.

Up to approximately 28 months after the First patient in or scheduled assessment
Progression-free survival (PFS) in each treatment arm
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

PFS is defined as the time from the date of first treatment to disease progression based on the Investigator assessment according to 2016 IMWG criteria or death from any cause, whichever happens first.

Up to approximately 28 months after the First patient in or scheduled assessment
Overall Survival (OS) in each treatment arm
Prazo: Up to approximately 28 months after the First patient in or scheduled assessment

OS is defined as the time from the date of first treatment to death from any cause.

Up to approximately 28 months after the First patient in or scheduled assessment
Immunogenicity of isatuximab and novel agents
Prazo: Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment

Incidence of anti-drug antibodies (ADAs) for novel agents (experimental arms) and isatuximab.

Multiple timepoints up to approximately 28 months after the First patient in or scheduled assessment
Disease-specific HRQL will be assessed using the European Organization for Research and Treatment of Cancer (EORTC) core quality of life questionnaire (QLQ-C30)
Prazo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

The EORTC QLQ-C30 will be used to assess cancer-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
Disease- and treatment-related quality of life will be assessed using the EORTC multiple myeloma module (QLQ-MY20) questionnaire
Prazo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

The EORTC QLQ-MY20 will be used to measure myeloma-specific HRQL, disease and treatment-related symptoms and impact of symptoms. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
Global impact of side effects will be assessed using the Functional Assessment of Cancer Therapy (FACT-G) (GP5)
Prazo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

A single item from the FACT-G GP5 will be used to assess the global impact of side effects. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
Estimate/Confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores using the Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales
Prazo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

Patient Global Impression of Severity (PGIS) and Patient Global Impression of Change (PGIC) scales will be utilized as anchors to estimate/confirm established clinically meaningful change scores for clinical outcome assessments (COAs)/domain scores. This endpoint will be assessed for Part 1 (dose optimization, independent and controlled experimental substudies) and Part 2 (expansion, independent and controlled experimental substudies).

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
The intensity of skeletal-related events (SRE)- related bone pain will be assessed using the skeletal-related bone pain numeric rating scale (SRE-BP-NRS) for control and experimental arms -Substudy 02
Prazo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.

The SRE-BP-NRS) will be used to assess the intensity of SRE-related bone pain (on average and at its worst) for control arm only

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at end of treatment and at first follow-up visit. The cycle is 28 days.
SRE Incidence for control and experimental arms- Substudy 02
Prazo: Continuous throughout study assessment (up to approximately 28 months)

SRE incidence, defined as the proportion of participants who experienced pathological fracture, radiation to bone, spinal cord compression, or surgery to bone as a first bone event.

Continuous throughout study assessment (up to approximately 28 months)
Time to First Occurrence of SRE Assessment for control and experimental arms (Substudy 02)
Prazo: Continuous throughout study assessment (up to approximately 28 months)

Time to first occurrence of SRE is defined as time from the date of randomization to the occurrence of first SRE.

Continuous throughout study assessment (up to approximately 28 months)
Assessment of Health care resource utilization related with SREs for control and experimental arms -Substudy 02
Prazo: On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.

The Health Care Resource Use-SREs questionnaire (HCRU-SREs) will be used to assess the use of health care resources associated with these events.

On Day1 Cycle 1, then every 2 cycles for the first year; then every 3 cycles thereafter, at End of treatment and at first follow-up visit. The cycle is 28 days.
To assess patient-reported visual functioning for experimental arm only -Substudy 03
Prazo: On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.

An NEI VFQ-25 will be used to assess patient-reported visual functioning.

On Day1 Cycle 1, End of treatment and at first follow-up visit. The cycle is 28 days.

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Patrocinador

Investigadores

  • Diretor de estudo: Clinical Sciences & Operations, Sanofi

Publicações e links úteis

A pessoa responsável por inserir informações sobre o estudo fornece voluntariamente essas publicações. Estes podem ser sobre qualquer coisa relacionada ao estudo.

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Real)

25 de janeiro de 2021

Conclusão Primária (Estimado)

13 de setembro de 2027

Conclusão do estudo (Estimado)

20 de abril de 2028

Datas de inscrição no estudo

Enviado pela primeira vez

20 de outubro de 2020

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de novembro de 2020

Primeira postagem (Real)

24 de novembro de 2020

Atualizações de registro de estudo

Última Atualização Postada (Real)

17 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

16 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • ACT16482
  • 2020-003024-16 (Número EudraCT)
  • U1111-1244-2598 (Identificador de registro: ICTRP)
  • 2024-514988-25 (Identificador de registro: CTIS)

Plano para dados de participantes individuais (IPD)

Planeja compartilhar dados de participantes individuais (IPD)?

SIM

Descrição do plano IPD

Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Não

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever